Premium
Neuropeptide Y antagonist improves bone density in ovariectomized female rats
Author(s) -
Tucci Michelle A,
Benghuzzi Hamed A,
McGuire Robert
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1118.2
Subject(s) - ovariectomized rat , endocrinology , medicine , neuropeptide y receptor , neuropeptide , estrogen , antagonist , estrogen receptor , bone remodeling , energy homeostasis , homeostasis , bone density , biology , receptor , osteoporosis , cancer , breast cancer
Neuropeptide Y plays a key role in the physiological control of energy homeostasis. The role of neuropeptide Y in ovariectomized animals has not been fully established. Multiple neuropeptide Y receptor subtypes are thought to mediate neuropeptide Y activity in both energy regulation and bone metabolism. We examined the role of neuropeptide Y(1) on bone density and strength in adult ovariectomized female rats compared with estrogen administration. A sustained‐dose of a neuropeptide Y(1) receptor antagonist (0.1 μg/day) reduced body weight similar to animals receiving sustained physiologic estrogen levels. In addition to body weight reductions, bone densities were increased and bone strength was improved over ovariectomized animals that were untreated. The histological and biomechanical evaluations showed Y(1) receptor antagonist had similar improvements compared with estrogen treated animals. These findings suggest neuropeptide Y(1) may play a role at the central nervous system and ultimately regulate energy homeostasis and bone metabolism.